Brief: Terns Pharmaceuticals Q3 Net Income USD -29.767 Million
14/11/2023 13:05
Nov 14 (Reuters) - Terns Pharmaceuticals Q3 operating expenses USD 33.184 million. * Q3 income from operations USD -33.184 million * Q3 pretax profit USD -29.709 million * Q3 basic EPS USD -0.42
Recent news on Terns Pharmaceuticals
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global
Brief: Merck Announces Expiration Of Hart-Scott-Rodino Act Waiting Period To Acquire Terns Pharmaceuticals
Brief: Merck Begins Tender Offer To Acquire Terns Pharmaceuticals, Inc.